• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    DaVita Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement

    7/17/25 4:01:26 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care
    Get the next $DVA alert in real time by email
    8-K
    false 0000927066 0000927066 2025-07-17 2025-07-17
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    Form 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (date of earliest event reported): July 17, 2025

     

     

    DAVITA INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    DE   1-14106   51-0354549
    (State or other jurisdiction
    of incorporation)
      (Commission
    File Number)
      (IRS Employer
    Identification No.)

    2000 16th Street

    Denver, CO 80202

    (Address of principal executive offices including Zip Code)

    (720) 631-2100

    (Registrant’s telephone number, including area code)

    Not applicable

    (Former name or former address, if changed since last report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class:

     

    Trading
    symbol(s):

     

    Name of each exchange
    on which registered:

    Common Stock, $0.001 par value   DVA   New York Stock Exchange

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    ☐

    Emerging growth company

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     
     


    Item 1.01.

    Entry into a Material Definitive Agreement.

    On July 17, 2025, DaVita Inc. (the “Company”) entered into a Seventh Amendment (the “Seventh Amendment”) to that certain Credit Agreement dated as of August 12, 2019 (as previously amended, restated, supplemented, or otherwise modified, and as further amended by the Seventh Amendment, the “Credit Agreement”), in each case, by and among the Company, its subsidiary guarantors, the lenders party thereto, and Wells Fargo Bank, National Association, as administrative agent, collateral agent and swingline lender (“Wells Fargo”).

    The Seventh Amendment, among other things, provides for (i) a repricing of the Company’s existing senior secured term loan “B” facility maturing in May 2031 (the “Extended Tranche B-1 Term Facility”; the Extended Tranche B-1 Term Facility as so repriced, the “Tranche B-2 Term Facility”, and the term “B” loans made thereunder, “Tranche B-2 Term Loans”) and (ii) an incremental borrowing of Tranche B-2 Term Loans in an aggregate principal amount of $250 million (the “Incremental Tranche B-2 Term Loans”).

    Pursuant to the Seventh Amendment and the Credit Agreement, the Tranche B-2 Term Loans (including the Incremental Tranche B-2 Term Loans) shall be denominated in U.S. dollars and shall bear interest, at the Company’s option, based on (i) the Base Rate (as defined below) plus the Applicable Margin (as defined below), or (ii) the forward-looking term rate based on the secured overnight financing rate that is published by CME Group Benchmark Administration Limited (“Term SOFR”) plus the Applicable Margin. The “Base Rate” with respect to the Tranche B-2 Term Facility is defined as the highest of (i) the Federal Funds Rate, as published by the Federal Reserve Bank of New York, plus 50 basis points, (ii) the prime commercial lending rate of Wells Fargo as established from time to time and (iii) Term SOFR for an interest period of one month plus 100 basis points; provided that if the Base Rate is negative it shall be deemed to be zero. The “Applicable Margin” for the Tranche B-2 Term Facility is 175 basis points in the case of Term SOFR loans and 75 basis points in the case of Base Rate loans. The “Applicable Margin” with respect to the Extended Tranche B-1 Term Facility before giving effect to the Seventh Amendment was 200 basis points for Term SOFR loans and 100 basis points for Base Rate loans.

    The Company used the proceeds of the Incremental Tranche B-2 Term Loans to repay a portion of its outstanding senior secured term “A” loans maturing in April 2028 in the amount of $250 million.

    The Company and its affiliates may from time to time engage certain of the lenders under the Credit Agreement to provide other banking, investment banking and financial services.

    The foregoing description of the Seventh Amendment does not purport to be complete and is qualified in its entirety by reference to the complete terms and conditions of the actual Seventh Amendment, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference. The Seventh Amendment has been incorporated by reference herein to provide stockholders with information regarding its terms. It is not intended to provide any other information about the Company or the Company’s subsidiaries that are guarantors thereunder, or other subsidiaries and affiliates of the Company. For example, the Seventh Amendment contains representations and warranties that were made solely for the benefit of the other parties to the Seventh Amendment and should not be relied upon as characterizations of the actual state of facts or condition of the Company or any of its subsidiaries.

     

    Item 2.03.

    Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

    The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference.


    Item 9.01.

    Financial Statements and Exhibits.

    (d) Exhibits.

     

    Exhibit
    Number

      

    Description

    10.1    Seventh Amendment, dated as of July 17, 2025, to that certain Credit Agreement, dated as of August 12, 2019, by and among DaVita Inc., certain subsidiary guarantors party thereto, the lenders party thereto, and Wells Fargo Bank, National Association, as administrative agent, collateral agent and swingline lender (including a conformed copy of the Credit Agreement, reflecting all amendments through the Seventh Amendment, attached as Annex A thereto).
    104.1    Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

        DAVITA INC.
    Date: July 17, 2025     By:  

    /s/ Joel Ackerman

          Joel Ackerman
          Chief Financial Officer and Treasurer
    Get the next $DVA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DVA

    DatePrice TargetRatingAnalyst
    3/6/2024$133.00Equal Weight
    Barclays
    8/7/2023$100.00 → $142.00Neutral → Buy
    UBS
    11/1/2022$97.00 → $72.00Buy → Hold
    Deutsche Bank
    10/31/2022$117.00 → $74.00Buy → Neutral
    UBS
    8/19/2022$106.00 → $117.00Buy
    UBS
    6/21/2022$110.00 → $90.00Underperform
    BofA Securities
    1/5/2022$114.00 → $125.00Hold
    Truist Securities
    10/29/2021$113.00 → $111.00Sector Perform
    RBC Capital
    More analyst ratings

    $DVA
    SEC Filings

    View All

    SEC Form 10-Q filed by DaVita Inc.

    10-Q - DAVITA INC. (0000927066) (Filer)

    8/5/25 5:03:37 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    DaVita Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - DAVITA INC. (0000927066) (Filer)

    8/5/25 4:07:44 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    DaVita Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement

    8-K - DAVITA INC. (0000927066) (Filer)

    7/17/25 4:01:26 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    $DVA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Schechter Adam H was granted 369 shares, increasing direct ownership by 9% to 4,699 units (SEC Form 4)

    4 - DAVITA INC. (0000927066) (Issuer)

    8/19/25 5:25:32 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    Director Yale Phyllis R was granted 369 shares, increasing direct ownership by 3% to 13,570 units (SEC Form 4)

    4 - DAVITA INC. (0000927066) (Issuer)

    8/19/25 5:24:37 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    Director Desoer Barbara J was granted 369 shares (SEC Form 4)

    4 - DAVITA INC. (0000927066) (Issuer)

    8/19/25 5:23:35 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    $DVA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    DaVita Inc. 2nd Quarter 2025 Results

    DENVER, Aug. 5, 2025 /PRNewswire/ -- DaVita Inc. (NYSE:DVA) announced financial and operating results for the quarter ended June 30, 2025. "We're reporting another solid quarter, fueled by our unwavering focus on patient care," said Javier Rodriguez, CEO of DaVita Inc. "We continued to deliver exceptional clinical outcomes for our patients, fostered a positive experience for our caregivers, and delivered on our financial commitments with disciplined execution across our businesses." Financial and operating highlights for the quarter ended June 30, 2025: Consolidated revenues were $3.380 billion.Operating income was $538 million and adjusted operating income was $551 million.Diluted earnings

    8/5/25 4:05:00 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    DaVita Inc. Schedules 2nd Quarter 2025 Investor Conference Call

    DENVER, July 17, 2025 /PRNewswire/ -- DaVita Inc. (NYSE:DVA), announced today that it will hold its quarterly conference call to discuss second quarter results on Tuesday, August 5, 2025, at 5:00 p.m. Eastern Time. The company plans to release its results after market close the same day. This call is also being webcast and can be accessed at the DaVita IR web page. You can join this call as follows:  Tuesday, August 5, 2025Starting at 5:00 p.m. EDTWebcast can be accessed using this link Dial in number: 877-918-6630International dial in: 517-308-9042 When calling in, please provide the operator the password "Earnings" and provide your name and company affiliation. Investors unable to listen t

    7/17/25 5:37:00 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    DaVita Statement on Government's Kidney Care Choices (KCC) Model Updates

    DENVER, May 30, 2025 /PRNewswire/ -- DaVita, a comprehensive kidney care company, issued the following statement in response to updates this week from the Center for Medicare and Medicaid Innovation (CMMI) related to its Kidney Care Choices (KCC) Model. It can be attributed to Misha Palecek, chief transformation officer for DaVita. "As a dedicated participant in the government's value-based care initiative and a pioneer in this field for the last twenty years, we applaud CMMI's decision to extend the Kidney Care Choices (KCC) Model for an additional year. We believe the investments made by CMMI and participants alike will result in long-term savings in the upcoming years. The program's emph

    5/30/25 2:35:00 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    $DVA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on DaVita with a new price target

    Barclays initiated coverage of DaVita with a rating of Equal Weight and set a new price target of $133.00

    3/6/24 8:09:27 AM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    DaVita upgraded by UBS with a new price target

    UBS upgraded DaVita from Neutral to Buy and set a new price target of $142.00 from $100.00 previously

    8/7/23 7:20:56 AM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    DaVita downgraded by Deutsche Bank with a new price target

    Deutsche Bank downgraded DaVita from Buy to Hold and set a new price target of $72.00 from $97.00 previously

    11/1/22 9:18:39 AM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    $DVA
    Leadership Updates

    Live Leadership Updates

    View All

    DaVita Appoints Jessica Hergenreter as Chief People Officer

    DENVER, Oct. 17, 2024 /PRNewswire/ -- DaVita, a leading provider of kidney care services, today announced Jessica (Jess) Hergenreter as its new chief people officer (CPO). In this position, Hergenreter will oversee DaVita's People Services team, leading initiatives to engage and uplift DaVita's more than 70,000 teammates (employees) worldwide. Earlier this year, DaVita was named as a Top Workplace by USA Today and one of America's Most Loved Companies by Newsweek. "Our incredible teammates are the difference makers for the care we provide to patients," said Javier Rodriguez, C

    10/17/24 1:00:00 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    DaVita Appoints David Maughan New Chief Operating Officer, Mike Staffieri Steps into Emeritus Role

    DENVER, Sept. 13, 2024 /PRNewswire/ -- DaVita, a leading provider of kidney care services, today announced that David Maughan will assume the role of chief operating officer. This appointment builds on Maughan's 18-year tenure at DaVita in a range of leadership roles. After a celebrated 11-year tenure as chief operating officer, Mike Staffieri will step into the role of chief operating officer emeritus. Both appointments are effective September 15, 2024. "It's an exciting time for DaVita! Dave's extensive experience in operations leadership coupled with his deep knowledge of DaVita's business positions him well to build upon our incredible foundation of operational excellence and lead our on

    9/13/24 8:00:00 AM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    DaVita Appoints New Chief Information Officer

    Madhu Narasimhan named to leadership role to accelerate technology-based innovations at DaVita  DENVER, May 13, 2024 /PRNewswire/ -- DaVita, a leading provider of kidney care services, today announced that Madhu Narasimhan will assume the role of chief information officer (CIO), effective June 3, 2024. In this leadership position, Narasimhan will be responsible for accelerating the implementation of DaVita's industry-leading health technology platforms. She will oversee DaVita's technology innovation strategy, including enterprise priorities like Center Without Walls™ (CWOW®),

    5/13/24 9:00:00 AM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    $DVA
    Financials

    Live finance-specific insights

    View All

    DaVita Inc. 2nd Quarter 2025 Results

    DENVER, Aug. 5, 2025 /PRNewswire/ -- DaVita Inc. (NYSE:DVA) announced financial and operating results for the quarter ended June 30, 2025. "We're reporting another solid quarter, fueled by our unwavering focus on patient care," said Javier Rodriguez, CEO of DaVita Inc. "We continued to deliver exceptional clinical outcomes for our patients, fostered a positive experience for our caregivers, and delivered on our financial commitments with disciplined execution across our businesses." Financial and operating highlights for the quarter ended June 30, 2025: Consolidated revenues were $3.380 billion.Operating income was $538 million and adjusted operating income was $551 million.Diluted earnings

    8/5/25 4:05:00 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    DaVita Inc. Schedules 2nd Quarter 2025 Investor Conference Call

    DENVER, July 17, 2025 /PRNewswire/ -- DaVita Inc. (NYSE:DVA), announced today that it will hold its quarterly conference call to discuss second quarter results on Tuesday, August 5, 2025, at 5:00 p.m. Eastern Time. The company plans to release its results after market close the same day. This call is also being webcast and can be accessed at the DaVita IR web page. You can join this call as follows:  Tuesday, August 5, 2025Starting at 5:00 p.m. EDTWebcast can be accessed using this link Dial in number: 877-918-6630International dial in: 517-308-9042 When calling in, please provide the operator the password "Earnings" and provide your name and company affiliation. Investors unable to listen t

    7/17/25 5:37:00 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    DaVita Inc. 1st Quarter 2025 Results

    DENVER, May 12, 2025 /PRNewswire/ -- DaVita Inc. (NYSE:DVA) announced financial and operating results for the quarter ended March 31, 2025. "Our strong first quarter performance demonstrates the stability and consistency of our operating model" said Javier Rodriguez, CEO of DaVita Inc. "We maintain a steadfast commitment to being the provider, employer and partner of choice and returning value to our shareholders." Financial and operating highlights for the quarter ended March 31, 2025: Consolidated revenues were $3.224 billion.Operating income was $439 million.Diluted earnings per share was $2.00.Operating cash flow was $180 million and free cash flow was $(45) million.Repurchased 3.7 milli

    5/12/25 4:05:00 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    $DVA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by DaVita Inc. (Amendment)

    SC 13G/A - DAVITA INC. (0000927066) (Subject)

    2/13/24 5:02:42 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    SEC Form SC 13G/A filed by DaVita Inc. (Amendment)

    SC 13G/A - DAVITA INC. (0000927066) (Subject)

    2/9/22 3:43:35 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care

    SEC Form SC 13D/A filed by DaVita Inc. (Amendment)

    SC 13D/A - DAVITA INC. (0000927066) (Subject)

    8/4/21 4:02:59 PM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care